Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.

Lukas AndereggenJanine FreyEmanuel Christ

Published in: Endocrine (2020)

Our long-term results indicate that chronic treatment with CAB in prolactinoma patients does not significantly modify serum IGF-1 levels. Bearing in mind the sample size of this study, continuing IGF-1 monitoring is not indicated in prolactinoma patients with long-term CAB therapy.

Keyphrases

end stage renal disease
ejection fraction
binding protein
newly diagnosed
growth hormone
stem cells
cell proliferation
mesenchymal stem cells
combination therapy